DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

UNAGI, a deep generative neural network, tracks IPF progression and identifies potential therapies by analyzing cell types and disease-related genes. The model autonomously learns and refines itself, ...

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

SAN DIEGO -- Two novel drugs improved lung function in idiopathic pulmonary fibrosis (IPF) in a pair of phase IIa trials, researchers reported here. In an open-label, single-arm trial of 46 patients ...

Even a disease as deadly as idiopathic pulmonary fibrosis (IPF) can start out as just a cough. But as the condition progresses, a person might experience up to 500 respiratory spasms per day.

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering. The IPF ...